Stockholm, February 28, 2023 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company during February issued 49,104 B shares for delivery of shares to participants in the 2019/2028 stock warrant program resolved at the Annual General Meeting on May 9, 2019. The shares were issued through an exercise of 49,104 warrants of series 2019/2028.
As of February 28, 2023, the last trading day of the month, the total number of shares in BioArctic AB amounts to 88,180,675 shares, of which 73,780,679 listed B shares and 14,399,996 unlisted A shares. The A share has ten votes per share and the B share has one vote per share. The total number of votes in the company amounts to 217,780,639.
—
This information is information that BioArctic is obliged to make public pursuant to the Financial Instruments Trading Act. The information was released for public disclosure, through the agency of the contact persons below, on February 28, 2023, at 18:00 a.m. CET.
For further information, please contact:
Oskar Bosson, VP Communications and Investor Relations
E-mail: oskar.bosson@bioarctic.se
Phone: +46 70 410 71 80
About BioArctic AB
BioArctic AB (publ) is a Swedish research-based biopharma company focusing on disease-modifying treatments for neurodegenerative diseases, such as Alzheimer’s disease, Parkinson’s disease and ALS. BioArctic focuses on innovative treatments in areas with high unmet medical needs. The company was founded in 2003 based on innovative research from Uppsala University, Sweden. Collaborations with universities are of great importance to the company together with its strategically important global partner Eisai in Alzheimer disease. The project portfolio is a combination of fully funded projects run in partnership with global pharmaceutical companies and innovative in-house projects with significant market and out-licensing potential. BioArctic’s Class B share is listed on Nasdaq Stockholm Large Cap (ticker: BIOA B). For more information about BioArctic, please visit www.bioarctic.com.